Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related ...

Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in vivo antibody discovery, announced today the issuance of a patent in Japan covering core innovations underlying its ...

The Direxion Daily S&P Biotech Bear 3X Shares ETF offers -3X daily leverage to the S&P Biotechnology Select Industry Index, primarily attracting short-term traders. LABD has lost 99.98% of its value ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

To share your story, or find out how to get involved with CNBC Cures, email CNBC.cures@cnbc.com China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

So, what will the early months of 2026 look like for the biotech sector? First, let me say that the biotech sector being 'en fuego' over the past three quarters has made my year as far as my portfolio ...

After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study. Founded by 5AM Ventures’ 4:59 ...